Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Placebo -Controlled, Randomized Study to Assess the Efficacy and Safety of Zenapax in Combination With CellCept, Cyclosporine, and Corticosteroids in Patients Undergoing Cardiac Transplantation.

NCT00048165 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT00048165
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00048165 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Placebo -Controlled, Randomized Study to Assess the Efficacy and Safety of Zenapax in Combination With CellCept, Cyclosporine, and Corticosteroids in Patients Undergoing Cardiac Transplantation.
Lead sponsor
Hoffmann-La Roche
Phase
Phase 4
Overall status
Completed
Start date
August 31, 1999
Completion date
August 31, 2002
Enrollment
434 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

heart transplantation